Dr Reddy’s to acquire Mayne Pharma US generic portfolio for $105 million

Under the terms of the agreement, Dr. Reddy’s will acquire the portfolio for an upfront payment of $90 million in cash, contingent payments of up to $15 million, consideration towards inventory and credits for certain accrued channel liabilities to be determined on the closing date.